ANNOVERA®
The Only Long-Lasting,
Procedure-Free Birth
Control

Educational Resources
For Healthcare Profesionals

 

 

Resources for Healthcare
Professionals

HOW TO PRESCRIBE ANNOVERA guide

A quick reference describing how to start patients on ANNOVERA whether they’re new to birth control or switching to ANNOVERA from other types of contraception.

ANNOVERA Anatomical Model Flashcard

An illustrated educational tool showing how ANNOVERA is inserted and where ANNOVERA rests in the vagina during use.

 

HCP RESOURCES

Use these links to learn more about
ANNOVERA.

ANNOVERA Videos for
Healthcare Professionals

Contemporary OB/GYN K-Cast Series

Rationale For A New Method Of Contraception.

Featuring Anita Nelson, MD, Professor and Chair of Obstetrics and Gynecology at Western University Health Sciences and Brian A. Bernick, MD, Cofounder and Chief Scientific Officer
of TherapeuticsMD.

Rationale for a New Method
of Contraception

Patient Satisfaction and Counseling

Patient Profiles

Clinical Data

Meet ANNOVERA Video

View by chapter:

 

 

Resources for
Your Patients

ANNOVERA Instructions For Use ANNOVERA Patient Brochure ANNOVERA Patient Brochure–Spanish

Download the ANNOVERA Birth
Control Tracker App:

ANNOVERA App Card
 

 

Connect With Us

844-ANNOVERA (844-266-6837) CustomerService@vitaCareRX.com Request a Representative Contact TherapeuticsMD Medical Affairs

 

IMPORTANT
SAFETY INFORMATION

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS

See full prescribing information for complete boxed warning.

  • Females over 35 years old who smoke should not use ANNOVERA.
  • Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive use.

CONTRAINDICATIONS

ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) is contraindicated and should not be used in women with a high risk of arterial or venous thrombotic diseases; current or history of breast cancer or other estrogen- or progestin-sensitive cancer; liver tumors, acute hepatitis, or severe (decompensated) cirrhosis; undiagnosed abnormal uterine bleeding; hypersensitivity to any of the components of ANNOVERA; and use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.


WARNINGS AND PRECAUTIONS

  • Stop ANNOVERA if a thrombotic or thromboembolic event occurs, and at least 4 weeks before and through 2 weeks after major surgery. Start ANNOVERA no earlier than 4 weeks after delivery, in females who are not breastfeeding. Consider cardiovascular risk factors before initiating in all females, particularly those over 35 years.
  • Discontinue if jaundice occurs.
  • Stop ANNOVERA prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir. ANNOVERA can be restarted 2 weeks following completion of this regimen.
  • Do not prescribe ANNOVERA for females with uncontrolled hypertension or hypertension with vascular disease. Monitor blood pressure and stop use if blood pressure rises significantly in females with well-controlled hypertension.
  • Monitor glucose in pre-diabetic or diabetic females taking ANNOVERA. Consider an alternate contraceptive method for females with uncontrolled dyslipidemias.
  • Patients using ANNOVERA who have a significant change in headaches or irregular bleeding or amenorrhea should be evaluated. ANNOVERA should be discontinued if indicated.
  • Other warnings include: gallbladder disease; depression; cervical cancer; increased serum concentrations of binding globulins; hereditary angioedema; chloasma (females who tend to develop chloasma should avoid exposure to the sun or UV radiation while using ANNOVERA); toxic shock syndrome (TSS) (if a patient exhibits symptoms of TSS, remove ANNOVERA, and initiate appropriate medical treatment); vaginal use (ANNOVERA may not be suitable for females with conditions that make the vagina more susceptible to vaginal irritation or ulceration).

ADVERSE REACTIONS

The most common adverse reactions reported in at least 5% of women who received ANNOVERA were: headache/migraine, nausea/vomiting, vulvovaginal mycotic infection/candidiasis, lower/upper abdominal pain, dysmenorrhea, vaginal discharge, urinary tract infection, breast pain/tenderness/discomfort, bleeding irregularities including metrorrhagia, diarrhea, and genital pruritus.


DRUG INTERACTIONS

Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of ANNOVERA or increase breakthrough bleeding. Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with ANNOVERA.


INDICATION

ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) is a progestin/estrogen combination hormonal contraceptive indicated for use by females of reproductive potential to prevent pregnancy.


Limitations of Use: ANNOVERA has not been adequately studied in females with a body mass index >29 kg/m2.


Please note that this information is not comprehensive. Please click here for the Full Prescribing Information, including BOXED WARNING.



Sign up to receive communications about health conditions, products, market research, and updates from TherapeuticsMD and its partners.

Thank you for registering!
You will receive more information about ANNOVERA.

Please Wait

844-ANNOVERA

844-266-6837